Suppressing SPTBN2 expression significantly increased the sensitivity of cisplatin-resistant NSCLC cells toward cisplatin, both in vitro and in vivo, through the induction of ferroptosis (Fig. 8). The gene discussed is SPTBN2; the disease is non-small cell lung carcinoma.